3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
7
Kidney Neoplasms
2
Urolithiasis
1
Stomatitis
1
Pneumoperitoneum
1
Neoplasm Metastasis
1
Lower Urinary Tract Symptoms
1
Invasive Bladder Cancer
1
Hydronephrosis
1
Gastrointestinal Stromal Tumors
1
Castrate-Resistant Prostate Cancer
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Interventions
Sunitinib
3
trastuzumab deruxtecan
1
ripretinib
1
guadecitabine
1
Thalidomide
1
Specimen Handling
1
Sodium Chloride
1
Psychiatric Rehabilitation
1
OSI 930
1
Nivolumab
1
Midazolam
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
Ipilimumab
1
Fentanyl
1
Erlotinib Hydrochloride
1
Early Intervention, Educational
1
Docetaxel
1
Counseling
1
Caffeine
1
CTLA-4 Antigen
1
7-hydroxystaurosporine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Stromal Tumors
×
Sodium Chloride
×
Genitourinary
×
Clear all
NCT01265810
2017-11-13
COMTT
Impaqtt Foundation
Phase 3
Completed
64 enrolled